Brief: Kiromic To Resubmit Two Expanded Inds To The FDA For Its Allogenic, Off-The-Shelf Gamma-Delta T Cell Therapies For Multiple Solid Tumors
09/03/2021 22:05
March 9 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC TO RESUBMIT TWO EXPANDED INDS TO THE FDA FOR ITS
ALLOGENIC, OFF-THE-SHELF GAMMA-DELTA T CELL THERAPIES FOR
MULTIPLE SOLID TUMORS
* KIROMIC BIOPHARMA INC - REVISED INDS HAVE PROTOCOLS WHICH
RETAIN
APPROXIMATELY 80% OF ORIGINAL INDS
* KIROMIC BIOPHARMA INC - SEES 2Q-2021 AS EXPECTED TIMELINE
FOR
PLANNED TWO IND RESUBMISSIONS
Source text for Eikon: ID:nBw2FLFv7a
Further company coverage: KRBP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site